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Background: The effectiveness of trivalent influenza vaccines may be reduced in older versus younger adults
because of age-related immunosenescence. The use of an adjuvant in such a vaccine is one strategy that may
combat immunosenescence, potentially by bolstering T-cell mediated responses.
Methods: This observer-blind study, conducted in the United States (US) and Spain during the 2008–2009 influenza
season, evaluated the effect of Adjuvant System AS03 on specific T-cell responses to a seasonal trivalent influenza
vaccine (TIV) in ≥65 year-old adults.
Medically-stable adults aged ≥65 years were randomly allocated to receive a single dose of AS03-adjuvanted TIV
(TIV/AS03) or TIV. Healthy adults aged 18–40 years received only TIV. Blood samples were collected on Day 0, Day
21, Day 42 and Day 180. Influenza-specific CD4+ T cells, defined by the induction of the immune markers CD40L,
IL-2, IFN-γ, or TNF-α, were measured in ex vivo cultures of antigen-stimulated peripheral blood mononuclear cells.
Results: A total of 192 adults were vaccinated: sixty nine and seventy three ≥65 year olds received TIV/AS03 and
TIV, respectively; and fifty 18 − 40 year olds received TIV. In the ≥65 year-old group on Day 21, the frequency of
CD4+ T cells specific to the three vaccine strains was superior in the TIV/AS03 recipients to the frequency in TIV
(p < 0.001). On Days 42 and 180, the adjusted-geometric mean specific CD4+ T-cell frequencies were also higher in
the TIV/AS03 recipients than in the TIV recipients (p < 0.001). Furthermore, the adjusted-geometric mean specific
CD4+ T-cell frequencies were higher in the ≥65 year-old recipients of TIV/AS03 than in the18 − 40 year old
recipients of TIV on Days 21 (p = 0.006) and 42 (p = 0.011).
Conclusion: This positive effect of AS03 Adjuvant System on the CD4+ T-cell response to influenza vaccine strains
in older adults could confer benefit in protection against clinical influenza disease in this population.
Trial registration: (Clinicaltrials.gov.). NCT00765076.
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Immune responses to influenza vaccination in older
adults tend to be weaker than in younger adults and this
has been attributed to the decline in immune function
associated with advancing age, termed immunosenes-
cence [1-6]. Strategies to improve vaccine immunogen-
icity in older adults include vaccination with a higher
dose of antigen [7,8] and the use of adjuvants [6]. How-
ever, conventional adjuvants based on aluminium salt do
not typically improve immunogenicity of influenza vac-
cines [6,9].
Adjuvant System AS03 (GlaxoSmithKline; GSK) is one of
a new generation of adjuvants including MF59 (Novartis)
and AF03 (Sanofi Pasteur) that have been shown to have
the potential to enhance the immunogenicity of influenza
vaccines [10-19]. AS03 contains α-tocopherol and squalene
in an oil-in-water emulsion [20] and has been shown to
enhance the immunogenicity of seasonal and potential
pandemic vaccines in older adults [19,21,22]. AS03 was in
the A/California/7/2009(H1N1)pdm09 vaccine that was
administered to a large number of people during the A
(H1N1) pandemic [20]. Preclinical experiments suggest
that AS03 enhances the adaptive responses to vaccine an-
tigens by triggering a transient innate response local to
the injection site [23].
Influenza vaccine immunogenicity is typically assessed by
serum antibody responses in haemagglutination-inhibition
(HI) tests [24,25]. However, cell-mediated immunity is
another and important arm of the adaptive immune re-
sponse: reports by Murasko et al. [26] and McElhaney
et al. [3,27] suggest that in older adults, cell-mediated re-
sponses play a significant role in protection from influenza
disease after vaccination. Also, cell-mediated responses
have been correlated with limiting disease severity in
healthy ≥18 year-old adults [28,29]. Recently, an AS03-
adjuvanted trivalent influenza vaccine has been found to
be more efficacious in preventing A(H3N2)-associated
influenza than the equivalent unadjuvanted vaccine in a
phase 3 trial of older adults [30]. The main aim of our
study was to evaluate the effect of TIV adjuvanted with
AS03 on T-cell responses in ≥65 year-old adults.
Methods
Study vaccines and vaccination
The investigational trivalent inactivated split influenza vac-
cine adjuvanted with AS03 (TIV/AS03; lot, DFLEA012B)
and control vaccine (TIV; Fluarix™a; lot, AFLUA348A)
were 2008-2009 seasonal vaccines supplied by GSK,
Dresden, Germany. Vaccinations were performed on Day
0. One dose of TIV/AS03 or TIV contained 15 μg Haem-
agglutinin (HA) from each of the three influenza strains
A/Brisbane/59/2007(H1N1), A/Uruguay/716/2007 (an A/
Brisbane/10/2007[H3N2]-like virus) and B/Brisbane/3/
2007 (a B/Florida/4/2006-like virus) (total 45 μg HA).AS03 (B formulation) contained 5.93 mg α-tocopherol,
5.34 mg squalene and 2.43 mg polysorbate-80 and was
supplied by GSK, Rixensart, Belgium. The vaccines
were administered by intramuscular injection (23G and
length suited to subject’s body mass) as 0.7 ml (TIV/
AS03) or 0.5 ml (TIV) into the deltoid muscle at study
entry (Day 0).
Study design and participants
This randomised, observer blind controlled study (NCT-
00765076) was conducted in the United States (US) and
Spain between October 2008 and December 2009. The
protocol, its amendments and other relevant study docu-
mentation were approved by the Institutional Review
Board for Baylor College of Medicine and Affiliated
Hospitals, the Comité Etico de Investigación Clínica del
Hospital Clinic de Barcelona, the Comité Etico de Inves-
tigación Clínica del Hospital La Paz, and the Comité
Etico de Investigación Clínica del Hospital Clínico San
Carlos, and the study was conducted in accordance with
good clinical practice guidelines, the Declaration of
Helsinki and all applicable regulatory requirements. Eli-
gible participants had provided written informed con-
sent. They were non-pregnant healthy adults aged 18-40
years or medically-stable adults aged ≥65 years at the
time of the vaccination. Adults ≥65 years were randomly
allocated (1:1) to receive TIV/AS03, (group TIV/AS03
[≥65]) or TIV (group TIV[≥65]). Adults 18-40 years re-
ceived TIV only (group TIV[18-40]) and the study was
open for this group. As the appearances of the investiga-
tional and control vaccines were different, the study was
observer-blind for the ≥65-years groups with vaccina-
tions performed by study personnel not involved in the
assessment of immunogenicity or safety/reactogenicity.
A randomisation list was generated by the sponsor using
SAS version 9.2 (SAS Institute Inc., NC, USA) and used
to number the vaccines. A randomisation blocking scheme
was used (respecting the treatment allocation 3:3:2 ratio
for the three study groups) and a treatment number
uniquely identified the vaccine to be administered to each
subject. The treatment allocation for the ≥65 year old sub-
jects at the investigator site was performed using an
internet-based system. The randomisation algorithm used
a minimisation procedure accounting for centre and age
strata 65-74 years and ≥75 years.
Study endpoints
The primary immunological endpoint was the frequency
of antigen-induced CD4+ T-cells specific for the three
combined vaccine influenza strains measured at Day 21,
in the groups of ≥65 year olds. Specific CD4+ T cells
were identified as CD4+ T cells which express two or
more of the following antigen-response markers after
short-term (20 hours) ex vivo stimulation: the CD40L
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TNF-α. The secondary immunological endpoints were
measured at Days 0, 21, 42 and 180 in all groups and
included the frequencies of vaccine-strain-specific CD4+
T-cells, and vaccine-strain-specific serum HI titres. Safety
and reactogenicity were assessed as secondary endpoints.
Exploratory endpoints included, in all subjects, vaccine
strain-specific neutralising antibody titres, and the frequen-
cies of vaccine-strain specific CD8+ T cells that expressed
two or more of the markers, CD40L, IL-2, IFN-γ, or
TNF-α; and, in a subset of subjects, the frequencies of
vaccine-strain-specific CD4+ or CD8+ T cells that expressed
Granzyme B and IFN-γ and/or IL-2, and, in those who
were cytomegalovirus (CMV)-seropositive at baseline, the
frequencies of CMV-specific T cells that expressed Gran-
zyme B and IFN-γ and/or IL-2.
Sample size
Sample sizes were set at 75 for each of the two ≥65 year
groups and at 50 in the TIV(18–40) group assuming five
subjects/per group would be non-evaluable. Seventy sub-
jects in each of the ≥65 year age groups would give 90%
power to demonstrate superiority of TIV/AS03 over TIV
in vaccine strain-specific CD4+ T-cell responses, assum-
ing a 1.5-fold greater response in the TIV/AS03 recipi-
ents compared with the TIV recipients (based on
unpublished observations), and with a coefficient of vari-
ation of 100% and a type I error of 5% (1-sided). Forty
five subjects in the TIV(18–40) group was calculated to
give 80% power to demonstrate non-inferiority of TIV/
AS03 in the ≥65 year age group compared with TIV in
the 18–40 year age group in terms of vaccine strain-
specific CD4+ T-cell responses assuming no difference
in this response to that for the TIV/AS03(≥65) group
and with a coefficient of variation of 100%, a type I error
of 5% and a non-inferiority margin of 1.5 fold. However,
this non-inferiority evaluation was not used as a con-
firmatory objective.
Ex vivo short-term T-cell re-stimulation assay
Influenza-specific T-cell responses were assessed using a
previously described validated method [14,31] adapted
from Maecker et al. [32]. Peripheral blood mononuclear
cells (PBMCs) were stimulated for two hours by the split
vaccine strain antigens in the presence of co-stimulatory
antibodies to CD28 and CD49d [33]. Brefeldin A was
added for a subsequent 18 hours incubation to promote
intracellular accumulation of cytokines [33]. Cells were
stained using fluorochrome-conjugated antibodies before
enumeration by flow cytometry. T cells were identified
by positive expression of CD3. CD4+ or CD8+ T cells
were typed as specific when they expressed two or more
immune markers among CD40L, IFN-γ, IL-2, TNF-α. In
some of the exploratory objectives, CD4+ or CD8+ Tcells were also typed as specific when they expressed
Granzyme B and IFN-γ or IL-2.
CMV-specific T-cell responses (in the Spain-enrolled sub-
set) were identified by the expression of Granzyme B and
IFN-γ or IL-2, using the same ex vivo method except that
PBMCs were stimulated by incubation with split-CMV
virus (to assess bystander activation of T cells [34,35]).
HI assay
Sera were analysed in a micro-titre HI assay as described
previously [36] with the vaccine virus strains used as an-
tigens. The serum titre was expressed as the reciprocal
of the highest dilution that showed complete inhibition
of haemagglutination. Seroconversion rate (SCR), sero-
protection rate (SPR) and seroconversion factor (SCF)
were defined according to regulatory criteria [24,25].
Neutralisation assay
Sera were subjected to heat treatment at 56°C for 30 mi-
nutes and then tested in triplicate as previously de-
scribed [37]. A constant amount of virus was mixed with
serial two-fold dilutions of serum samples, added to
Madin-Darby Canine Kidney cell cultures and incubated
for 7 days at 37°C. After incubation, virus replication was
determined by haemagglutination of red blood cells. The
50% neutralisation titre of a serum was calculated by the
Reed and Muench method [38].
Safety/reactogenicity assessments
Injection site adverse events (AEs; ecchymosis, pain,
redness and swelling) and systemic AEs (generalised/
widespread arthralgia, fatigue, gastrointestinal symp-
toms, headache, generalised/widespread myalgia, shiver-
ing and fever) were solicited daily for 7 days after
vaccination. Unsolicited AEs and their intensities were
recorded for 21 days after vaccination. The intensities of
ecchymosis, redness and swelling were graded as fol-
lows: Grade 1, >20– ≤ 50 mm; Grade 2, >50– ≤ 100 mm;
and Grade 3, >100 mm. Daily body temperature was
graded as follows: Grade 1, 38.0– < 38.5°C; Grade 2,
38.5– < 39.0°C; and Grade3, 39.0– ≤ 40.0°C. The inten-
sities of other AEs, including unsolicited AEs were
graded as follows: Grade 1, “easily tolerated” (“painful
on touch” for injection site pain); Grade 2, “interferes
with normal activity” (or “painful when limb is moved”
for injection site pain); and Grade 3, “prevents normal
activity” (or “considerable pain at rest” for injection site
pain). Data on unsolicited medically-attended AEs were
recorded up to Day 180. Data on serious adverse events
(SAEs) and any cases of potential Immune Mediated
Disease (pIMD, including diseases with clear autoimmune
aetiology and other inflammatory and/or neurologic disor-
ders with or without an autoimmune aetiology) were
collected during the whole study period (1 year). An
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solicited systemic and unsolicited AEs, as well as for SAEs
and pIMDs.
The use of medication during the study was recorded
from Day 0 to Day 180, and was reviewed by the investiga-
tor for any potential relationship with a study measure-
ment. The medication was considered as prophylactic
when it was administered in the absence of any symptom
and in anticipation of a reaction to the vaccination.
Statistical analysis
The primary objective was to demonstrate in vaccinated
subjects ≥65 years old, the superiority of TIV/AS03 over
TIV at the 5% significance level (1-sided), by having the
lower limit of the 90% confidence interval (CI) greater
than 1 of the adjusted geometric mean ratio (GMR) of
vaccine influenza strain-specific CD4+ T-cell frequencies
at Day 21. Statistical analyses of the secondary and ex-
ploratory endpoints were descriptive. For the analyses of
CD4+ T-cell responses between groups, a likelihood-based
mixed effect ANCOVA model for repeated measurement
was used to analyse the post-vaccination log-transformed
frequencies of influenza-specific CD4+ T cells. The model
included vaccine group, visit, and vaccine group by visit
interactions as fixed effects and the pre-vaccination log-
transformed frequency as covariate (resulting in the calcu-
lation of the adjusted geometric mean frequency [GMF]).
An unstructured covariance matrix was used to account
for the repeated measurements among subjects. The
goodness of fit Bayesian Information Criteria statistic
(SBIC) was used to assess the need of a separate covari-
ance matrix for each treatment. At each time point and
for each group, the adjusted geometric mean of post-
vaccination specific CD4+ T-cell frequency was computed
together with its 90% CI. The ratios of TIV/AS03(≥65)
over TIV(≥65) or over TIV(18 − 40) were calculated with
their 90% CIs. Computation of geometric mean titres
(GMT) and SCFs, and their 95% CIs, used Student’s t-dis-
tribution on log-transformed data that was assumed to be
normally distributed with unknown variance. Exact 95%
CIs were calculated for SCRs, SPRs and the safety
endpoints. Pearson correlation coefficients (r) were cal-
culated on the log-transformed values of comparisons
of fold-changes (Day 21 over Day 0) between vaccine
strain-specific HI titres and CD4+ T-cell frequencies.
SAS (version 9.2, SAS Institute Inc., NC, USA) was used
for all computations. Titre values in the text are re-
ported to two significant figures.
Results
Study population
A total of 192 adults were enrolled and, of the ≥65 year
olds, 69 were vaccinated with TIV/AS03 and 73 were
vaccinated with TIV. Fifty 18–40 year olds were alsovaccinated with TIV (Figure 1). One hundred and six
subjects were from Spain and 86 from the US. Two sub-
jects did not complete the study, but were vaccinated.
One subject (TIV/AS03[≥65] group) did not complete
due to a fatal myocardial infarction; and the other sub-
ject (TIV[18 − 40] group) withdrew consent for a reason
not related to any AE. Twenty subjects were excluded
from the per protocol immunogenicity cohorts. In these
per protocol cohorts, the mean ages at enrolment of the
two ≥65 year groups were both 71 years and the mean
age of the 18 − 40 years group was 26 years. The major-
ity of subjects in all groups were White Caucasian
(Table 1). With respect to the proportion of female sub-
jects, there was an imbalance between the three groups
(50%, 41% and 54% in the TIV/AS03[≥65], TIV[≥65] and
TIV[18 − 40], respectively). In the three influenza sea-
sons preceding the study, 71%, 78% and 48% of the sub-
jects in the TIV/AS03(≥65), TIV(≥65) and TIV(18 − 40)
groups, respectively, had received influenza vaccination.
Immunogenicity
On Day 21 in the ≥65 year old subjects, TIV/AS03 was
superior to TIV by a factor of 1.64 (p < 0.001) in terms
of the adjusted-GMR of frequencies of CD4+ T cells spe-
cific to the three (pooled) vaccine strains per 106 CD4+
T cells (Table 2). On Days 42 and 180 in the ≥65 year
old subjects, the adjusted-GMRs of vaccine strain-specific
CD4+ T-cell frequencies in the TIV/AS03 group over the
TIV group were 1.70 (p < 0.001) and 1.40 (p < 0.001), re-
spectively. On Days 21 and 42, adjusted-GMRs of the spe-
cific CD4+ T-cell frequencies in the TIV/AS03(≥65) group
over the TIV(18–40) group were 1.35 (p = 0.006) and
1.30 (p = 0.011), respectively, whereas on Day 180, the
adjusted-GMR was 0.99 (p = 0.860).
Pre-vaccination, the median frequencies of (pooled)
vaccine influenza strain-specific CD4+ T cells (per 106
CD4+ T cells) were 1300 and 1200 in the TIV/AS03(≥65)
and TIV(≥65) groups; whereas the median frequency
was 2000 in the TIV(18–40) group. On Day 21, the re-
spective median frequencies of these specific CD4+ T
cells were 3500, 2300 and 3000, and on Day 180 they
were 2300, 1500 and 2600 (Figure 2A). Each of the im-
mune markers was detected in influenza-specific CD4+
T cells (Figure 2B) both before and after vaccination in
the three groups. Each of the vaccine-strain antigens also
stimulated specific CD4+ T-cell responses (Figure 2B).
For A/Brisbane(H1N1), the pre-vaccination and Day 21
median frequencies in the TIV/AS03(≥65) group were
440 and 1000 respectively; whereas in the TIV(≥65), they
were 400 and 630, respectively, and in TIV(18 − 40), they
were 860 and 930, respectively. For A/Uruguay(H3N2),
the corresponding median frequencies in the TIV/AS03
(≥65) group were 360 and 1000, in the TIV(≥65) group,
were 360 and 590, and in the TIV(18 − 40) group, were
Figure 1 The allocation and elimination of subjects during the course of the study. The reasons for elimination from the Total Vaccinated
cohort (TVC) to give the per protocol immunogenicity cohorts are described to the left of each box. Safety was assessed in the TVC.
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frequencies in the TIV/AS03(≥65) group were 650 and
1800, in the TIV(≥65) group, were 600 and 1300, and in
the TIV(18 − 40) group, were 1300 and 1900. The rela-
tive proportions of the different influenza-specific CD4+
T-cell phenotypes appeared similar for the three groups
(Figure 2B and Table 3). These phenotypes were mainly
polyfunctional, and the most prevalent was CD40L+ IL-
2+ IFN-γ+ TNF-α+ (Table 3). About half of the CD4+ T
cells were IFN-γ+. The frequencies of a particular
vaccine-strain specific CD4+ T-cell phenotype subset
relative to the all vaccine-strain specific CD4+ T-cells
appeared similar pre- and post-vaccination.Table 1 Demographic characteristics of the per-protocol coho
Characteristic TIV/
(N =
Age, months; mean (SD) 71.4
Gender; n (%) Female 31 (5
Male 31 (5
Race; n (%) American Indian or Alaskan native 0 (0)
African heritage/African American 0 (0)
Asian–Central/S. Asian heritage 0 (0)
Asian–E. Asian heritage 0 (0)
Asian–Japanese heritage 0 (0)
Asian–S. E. Asian heritage 0 (0)
Native Hawaiian/pacific islander 0 (0)
White - Arabic/N. African heritage 0 (0)
White - Caucasian/European heritage 62 (1
Other 0 (0)
SD, standard deviation; TIV, trivalent influenza vaccine; TIV/AS03, AS03-adjuvanted tNo influenza-specific CD8+ T-cell response to vaccin-
ation was detected in any of the three groups (Figure 3).
Vaccination also did not appear to affect the frequency
of influenza-specific CD4+ or CD8+ T cells expressing
Granzyme B and at least IFN-γ, and/or IL-2 (Figure 4).
There was no suggestion of bystander activation from
the evaluation of the frequencies of CMV-specific CD4+
and CD8+ T cells expressing Granzyme B and at least
IFN-γ, and/or IL-2 in CMV-seropositive subjects, be-
cause these frequencies appeared unaffected by vaccin-
ation (Additional file 1).
Serum-HI titres (and SPRs and SCFs) and neutralisa-
tion titres, were determined before and after vaccinationrt
AS03(≥65) TIV(≥65) TIV(18–40) Total
62) (N = 66) (N = 44) (N = 172)
(5.5) 71.3 (5.3) 26.3 (5.1) 59.8 (20.4)
0) 27 (41) 24 (55) 82 (48)
0) 39 (59) 20 (46) 90 (52)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
0 (0) 2 (4.5) 2 (1.2)
0 (0) 2 (4.5) 2 (1.2)
0 (0) 0 (0) 0 (0)
1 (1.5) 1 (2.3) 2 (1.2)
0 (0) 0 (0) 0 (0)
0 (0) 1 (2.3) 1 (0.6)
00) 64 (97) 37 (84) 163 (95)
1 (1.5) 1 (2.3) 2 (1.2)
rivalent influenza vaccine.
Table 2 Influenza-specific CD4+ T-cell responses to vaccination
Day CD4+ T cellsa producing at least two different markers (CD40L, IL-2, TNF-α, IFN-γ) / 106 CD4+ T cells
Adjusted geometric meanb (90% CI; N)
TIV/AS03(≥65) TIV(≥65) TIV(18–40)
21 3634 (3134–4214; N = 62) 2222 (1954–2527; N = 58) 2683 (2425–2969; N = 43)
42 2873 (2523–3271; N = 61) 1688 (1523–1871; N = 60) 2217 (2001–2457; N = 44)
180 2234 (2011–2482; N = 60) 1601 (1443–1776; N = 60) 2265 (2108–2433; N = 42)
Ratio (90% CI; p-value)
TIV/AS03(≥65), TIV(≥65) TIV/AS03(≥65), TIV(18–40)
21 1.64 (1.35–1.99; p < 0.001)c 1.35 (1.13–1.62; p = 0.006)d
42 1.70 (1.44–2.00; p < 0.001) 1.30 (1.10–1.53; p = 0.011)
180 1.40 (1.21–1.61; p < 0.001) 0.99 (0.87–1.12; p = 0.860)
aAfter in vitro stimulation with split vaccine antigens from all three (pooled) strains.
bNote that in the ANCOVA model, only the CD4+ T-cell frequency post-vaccination was considered as a dependent variable. The pre-vaccination CD4+ T-cell
frequency was considered as a covariate in the calculation of the adjusted geometric means.
cPrimary study objective.
dSecondary study objective. TIV/AS03: AS03-adjuvanted trivalent influenza vaccine.
Figure 2 Influenza-specific CD4+ T-cell responses to vaccination in the immunogenicity cohort. Box and whisker plots describing the
frequency of CD4+ T cells (A) specific for the three (pooled) influenza vaccine strains and identified as expressing two or more immune markers
among CD40L, IL-2, TNF-α and IFN-γ after a short term in vitro stimulation; (B-left) specific for each of the individual influenza vaccine strains and
induced to express at least two immune markers; and (B-right) specific for the three (pooled) influenza vaccine strains and induced to express
one defined immune marker (x-axis) and at least one other. The whiskers extend to the lowest (Min) and highest (Max) values; the box extends
to the 1st quartile (Q1) and 3rd quartiles (Q3) in which the median is marked by a horizontal line.
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Table 3 CD4+ T-cell responses in terms of different immune marker expression profiles
Immune-related marker expression (+/-) Geometric mean frequenciesa (percentages relative to totals) of CD4+ T cells producing
immune-related markers/106 CD4+ T cellsb
IFN-γ TNF-α IL-2 CD40L Day 0 Day 21 Day 42 Day 180
TIV/AS03(≥65)
+ + + + 490 (44) 1075 (31) 937 (37) 670 (37)
+ - + + 112 (10) 441 (13) 327 (13) 213 (12)
- + + + 171 (15) 425 (12) 355 (14) 284 (16)
- - + + 114 (10) 356 (10) 308 (12) 172 (10)
+ + - + 27 (2) 179 (5) 108 (4) 40 (2)
+ - - + 26 (2) 270 (8) 134 (5) 62 (3)
- + - + 32 (3) 106 (3) 67 (3) 50 (3)
- - - + 85 (8) 259 (8) 139 (5) 178 (10)
+ + + - 19 (2) 61 (2) 48 (2) 54 (3)
+ - + - 6 (1) 35 (1) 17 (1) 13 (1)
- + + - 3 (0) 18 (1) 12 (0) 6 (0)
- - + - 8 (1) 38 (1) 28 (1) 11 (1)
+ + - - 4 (0) 28 (1) 17 (1) 12 (1)
+ - - - 23 (2) 149 (4) 61 (2) 20 (1)
- + - - 3 (0) 11 (0) 3 (0) 4 (0)
Total 1124 (100) 3451 (100) 2562 (100) 1788 (100)
TIV(≥65)
+ + + + 554 (45) 779 (33) 598 (38) 463 (34)
+ - + + 115 (9) 340 (15) 222 (14) 157 (12)
- + + + 187 (15) 327 (14) 229 (15) 209 (16)
- - + + 127 (10) 278 (12) 174 (11) 114 (8)
+ + - + 35 (3) 82 (3) 43 (3) 31 (2)
+ - - + 25 (2) 144 (6) 54 (3) 39 (3)
- + - + 51 (4) 49 (2) 44 (3) 37 (3)
- - - + 70 (6) 190 (8) 109 (7) 198 (15)
+ + + - 12 (1) 35 (1) 28 (2) 41 (3)
+ - + - 8 (1) 17 (1) 9 (1) 9 (1)
- + + - 4 (0) 12 (1) 8 (1) 6 (0)
- - + - 10 (1) 27 (1) 16 (1) 9 (1)
+ + - - 5 (0) 11 (0) 6 (0) 9 (1)
+ - - - 17 (1) 51 (2) 25 (2) 20 (2)
- + - - 3 (0) 4 (0) 3 (0) 4 (0)
Total 1222 (100) 2344 (100) 1568 (100) 1347 (100)
Immune-related marker expression (+/-) Geometric mean frequenciesa (percentages relative to totals) of CD4+ T cells producing
immune-related markers/106 CD4+ T cellsb
IFN-γ TNF-α IL-2 CD40L Day 0 Day 21 Day 42 Day 180
TIV(18–40)
+ + + + 832 (42) 1160 (32) 1007 (36) 863 (34)
+ - + + 220 (11) 530 (14) 402 (14) 290 (11)
- + + + 239 (12) 347 (9) 283 (10) 265 (10)
- - + + 182 (9) 389 (11) 306 (11) 256 (10)
+ + - + 69 (4) 145 (4) 136 (5) 87 (3)
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Table 3 CD4+ T-cell responses in terms of different immune marker expression profiles (Continued)
+ - - + 50 (3) 230 (6) 139 (5) 122 (5)
- + - + 56 (3) 101 (3) 87 (3) 53 (2)
- - - + 181 (9) 340 (9) 194 (7) 276 (11)
+ + + - 67 (3) 121 (3) 95 (3) 199 (8)
+ - + - 13 (1) 61 (2) 31 (1) 46 (2)
- + + - 7 (0) 19 (1) 11 (0) 7 (0)
- - + - 13 (1) 92 (3) 25 (1) 11 (0)
+ + - - 9 (0) 34 (1) 22 (1) 25 (1)
+ - - - 19 (1) 89 (2) 69 (2) 44 (2)
- + - - 4 (0) 8 (0) 5 (0) 4 (0)
Total 1961 (100) 3669 (100) 2814 (100) 2548 (100)
aNote that the geometric mean frequencies are not adjusted (see Table 2).
bAfter in vitro stimulation with split vaccine antigens from all three (pooled) strains.
TIV, trivalent influenza vaccine; TIV/AS03, AS03-adjuvanted trivalent influenza vaccine.
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http://www.biomedcentral.com/1471-2334/14/425in each group (Figure 5 and Table 4). On Day 21, the SCFs
for TIV/AS03(≥65) were 6.4, 15 and 7.6 against A/Bris-
bane(H1N1), A/Uruguay(H3N2) and B/Brisbane vaccine
influenza strains, respectively. The corresponding SCFs
for TIV(≥65) were 4.7, 9.4 and 5.2; and for TIV(18 − 40)
were 11, 11 and 7.4. On Day 180, the range of SCFs for
TIV/AS03(≥65) were 2.3–5.5, for TIV(≥65) were 2.2–3.4,
and for TIV(18 − 40) were 4.0–4.6, suggesting a persist-
ence of the antibody response in all treatment groups. No
strong correlations were identified between the antibody
and CD4+ T-cell responses to vaccination (i.e. the fold
changes at Day 21 over Day 0) in all three groups consid-
ered together because Pearson r was less than 0.3 for each
vaccine-specific set of responses (Figure 6).Figure 3 Influenza-specific CD8+ T-cell responses to vaccination
in the per protocol immunogenicity cohort. Box and whisker
plots describing the frequency of CD8+ T cells specific for the three
(pooled) influenza vaccine strains and induced to express at least
two immune markers. The whiskers extend to the lowest (Min)
and highest (Max) values; the box extends to the 1st quartile (Q1)
and 3rd quartiles (Q3) in which the median is marked by a
horizontal line.
Figure 4 Influenza-specific cytotoxic CD4+ and CD8+ T-cell
responses to vaccination in the per protocol immunogenicity
cohort. Box and whisker plots describing the frequency of CD4+ or
CD8+ T cells specific for the three (pooled) influenza vaccine strains and
induced to express Granzyme B and IFN-γ and/or IL-2 (Spanish subjects
only). For the TIV/AS03(≥65), TIV(≥65) and TIV(18–40) groups, N = 30–32,
35–36 and 24–25, respectively. The whiskers extend to the lowest (Min)
and highest (Max) values; the box extends to the 1st quartile (Q1) and
3rd quartiles (Q3) in which the median is marked by a horizontal line.
Figure 5 Influenza-specific antibody responses to vaccination in the per protocol immunogenicity cohort. Histograms describing
geometric mean titres (GMT) for haemagglutinin inhibition, percentage seroprotection rates, and neutralisation GMTs at Day 0, Day 21, Day 42
and Day 180.
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The most common injection site solicited symptom was
pain and was more frequently reported in TIV/AS03
(≥65) (62%) and TIV(18 − 40) (70%) groups than in the
TIV(≥65) group (21%) (Table 5). Injection site solicited
symptoms lasted for a mean duration of 2.3 − 3.5 days
(TIV/AS03[≥65]), 2.0 days (TIV[18 − 40]), and 1.6 −
5.0 days (TIV[≥65]). No grade 3 injection site solicited
symptoms were reported. Fatigue, headache and myalgia
were the most frequently reported systemic solicited
symptoms in the three groups. Most of the systemic
solicited symptoms were more commonly reported in
the TIV/AS03(≥65) and TIV(18 − 40) groups, than in the
TIV(≥65) group. Grade 3 solicited symptoms were infre-
quently reported in all groups. The only grade 3 solicited
systemic AEs reported were fever (1.4% in the TIV/AS03
(≥65) group) and shivering (2.0% in the TIV(18 − 40)group). The percentages of subjects experiencing at least
one unsolicited AE during the 21 day follow-up period
were 19% (TIV/AS03[≥65]), 29% (TIV[≥65]) and 30%
(TIV[18 − 40]). The percentages of subjects reporting
grade 3 unsolicited AEs were 2.9%, 2.7% and 2.0% in these
three groups, respectively. No grade 3 unsolicited AEs
were considered as related to vaccination. Between Day 0
and Day 180, unsolicited medically-attended AEs were re-
ported by 35%, 29% and 26% of subjects in the TIV/AS03
(≥65), TIV(≥65), and TIV(18 − 40) groups, respectively,
but none were considered related to vaccination. During
the year follow-up, no pIMDs were reported. SAEs were
reported by 17 subjects (5, TIV/AS03[≥65]; 11, TIV[≥65];
and 1, TIV[18 − 40]). One subject in the TIV/AS03
[≥65] group, aged 84 years, died from myocardial infarc-
tion at Day 256. None of the SAEs were considered re-
lated to vaccination.
Table 4 HI seroconversion rates and seroconversion
factors in response to vaccination
Group Day N A/Brisbane A/Uruguay B/Brisbane
% seroconversion rate (95% CI)a
TIV/AS03 (≥65) 21 62 58 (45–71) 84 (72–92) 71 (58–82)
42 61 54 (41–67) 79 (66–88) 62 (49–74)
180 62 26 (15–39) 58 (45–71) 35 (24–49)
TIV(≥65) 21 66 48 (36–61) 76 (64–86) 58 (45–70)
42 65 38 (27–51) 68 (55–79) 54 (41–66)
180 66 24 (14–36) 42 (30–55) 33 (22–46)
TIV(18-40) 21 43 67 (51–81) 77 (61–88) 67 (51–81)
42 44 66 (50–80) 68 (52–81) 57 (41–72)
180 43 53 (38–69) 46 (31–62) 46 (31–62)
Seroconversion factor (95% CI)a
TIV/AS03 (≥65) 21 62 6.4 (4.5–9.0) 15 (11–22) 7.6 (5.6–10)
42 61 5.1 (3.7–7.0) 12 (8.5–17) 5.4 (4.0–7.2)
180 62 2.3 (1.8–3.0) 5.5 (4.1–7.3) 2.8 (2.2–3.4)
TIV(≥65) 21 66 4.7 (3.4–6.6) 9.4 (6.6–13) 5.2 (3.8–7.1)
42 65 3.9 (2.8–5.4) 6.4 (4.7–8.6) 4.1 (3.1–5.4)
180 66 2.2 (1.7–3.0) 3.4 (2.5–4.6) 2.5 (1.9–3.1)
TIV(18-40) 21 43 11 (6.3–18) 11 (7.2–18) 7.4 (4.7–12)
42 44 8.9 (5.3–15) 7.9 (5.3–12) 5.8 (3.7–8.9)
180 43 4.6 (2.9–7.2) 4.5 (3.0–6.9) 4.0 (2.8–5.8)
aValues reported at two significant figures.
TIV, trivalent influenza vaccine; TIV/AS03, AS03-adjuvanted trivalent
influenza vaccine.
Figure 6 Scatter plot comparisons of log-transformed values of
fold-changes (Day 21 versus Day 0) of HI titres and frequencies
of CD4+ T cells expressing at least two immune markers specific
for the three vaccine strains, in samples from all three groups
of the Per Protocol cohort (N = 120, 120 and 118; upper, middle
and lower graphs, respectively). Pearson correlation coefficients (r)
and related trend line are shown for each comparison.
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ported by 64%, 53% and 54% of the subjects in the TIV/
AS03(≥65), TIV(≥65), and TIV(18–40) groups, respect-
ively. This included antipyretic medication, which was
reported by 30%, 25% and 40% of the subjects in the
TIV/AS03(≥65), TIV(≥65), and TIV(18–40) groups, re-
spectively. No use of prophylactic antipyretic medication
was reported.
Discussion
The principal finding of this study is that TIV/AS03 is
superior to TIV in that the inclusion of AS03 in TIV sig-
nificantly enhanced vaccine antigen-specific CD4+ T-cell
responses in ≥65 years-old adults on Day 21. This effect
of TIV/AS03 was also evident for specific CD4+ T-cell
responses against the three individual vaccine strains for
the 180 day observation period.
Previous studies using the same methodology to meas-
ure T-cell responses have shown that AS03 formulated in
A(H5N1) or A/California/7/2009(H1N1)pdm09 pandemic
vaccines also induce stronger polyfunctional CD4+ T-cell
responses than non-adjuvanted vaccine in adults aged
18 − 60 years [14,31] and in older adults [21]. The
similarity of the marker profile of the influenza specificCD4+ T cells elicited by the adjuvanted and non-
adjuvanted vaccines indicates that AS03 affects primar-
ily the magnitude of the specific CD4+ T-cell response
rather than qualitative changes in the immune marker
profile. This was also observed using different method-
ology in another study evaluating the effect on the im-
mune response of the oil-in-water based adjuvant MF59
included in an A(H5N1) vaccine [39].
No influenza-specific CD8+ T-cell responses were de-
tected after vaccination. Elsewhere, no specific CD8+ T-cell
responses were detected with A(H5N1) and A(H1N1)
pdm09 inactivated vaccines [14,21,31]. This does not
Table 5 Solicited injection site and systemic symptoms in
response to vaccination
Solicited
symptom
% of subjects (95% CI) reporting symptoms,
Day 0–6a
All grades Grade 1 Grade 2 Grade 3
TIV/AS03(≥65) (N = 69)
Injection site
Ecchymosisb 2.9 (0.4–10) 2.9 (0.4–10) 0.0 (0.0–5.2) 0.0 (0.0–5.2)
Painc 62 (50–74) 52 (40–64) 10 (4.2–20) 0.0 (0.0–5.2)
Rednessb 7.2 (2.4–16) 5.8 (1.6–14) 1.4 (0.0–7.8) 0.0 (0.0–5.2)
Swellingb 12 (5.1–22) 8.7 (3.3–18) 2.9 (0.4–10) 0.0 (0.0–5.2)
Systemic
Arthralgiacd 20 (12–32) 15 (7.2–25) 5.8 (1.6–14) 0.0 (0.0–5.2)
Fatiguecd 32 (21–44) 17 (9.3–28) 15 (7.2–25) 0.0 (0.0–5.2)
Gastrointestinalc 8.7 (3.3–18) 5.8 (1.6–14) 2.9 (0.4–10) 0.0 (0.0–5.2)
Headachec 32 (21–44) 23 (14–35) 8.7 (3.3–18) 0.0 (0.0–5.2)
Myalgiacd 25 (15–37) 17 (9.3–28) 7.2 (2.4–16) 0.0 (0.0–5.2)
Shiveringcd 16 (8.2–27) 12 (5.1–22) 4.3 (0.9–12) 0.0 (0.0–5.2)
Temperaturee 2.9 (0.4–10) 1.4 (0.0–7.8) 0.0 (0.0–5.2) 1.4 (0.0–7.8)
TIV(≥65) (N = 73)
Injection site
Ecchymosisb 1.4 (0.0–7.4) 1.4 (0.0–7.4) 0.0 (0.0–4.9) 0.0 (0.0–4.9)
Painc 21 (12–32) 18 (9.8–29) 2.7 (0.3–9.5) 0.0 (0.0–4.9)
Rednessb 0.0 (0.0–4.9) 0.0 (0.0–4.9) 0.0 (0.0–4.9) 0.0 (0.0–4.9)
Swellingb 1.4 (0.0–7.4) 1.4 (0.0–7.4) 0.0 (0.0–4.9) 0.0 (0.0–4.9)
Systemic
Arthralgiacd 4.1 (0.9–12) 1.4 (0.0–7.4) 2.7 (0.3–9.5) 0.0 (0.0–4.9)
Fatiguecd 16 (8.8–27) 12 (5.8–22) 4.1 (0.9–12) 0.0 (0.0–4.9)
Gastrointestinalc 5.5 (1.5–13) 2.7 (0.3–9.5) 2.7 (0.3–9.5) 0.0 (0.0–4.9)
Headachec 9.6 (3.9–19) 8.2 (3.1–17) 1.4 (0.0–7.4) 0.0 (0.0–4.9)
Myalgiacd 11 (4.9–21) 9.6 (3.9–19) 1.4 (0.0–7.4) 0.0 (0.0–4.9)
Shiveringcd 0.0 (0.0–4.9) 0.0 (0.0–4.9) 0.0 (0.0–4.9) 0.0 (0.0–4.9)
Temperaturee 0.0 (0.0–4.9) 0.0 (0.0–4.9) 0.0 (0.0–4.9) 0.0 (0.0–4.9)
TIV(18-40) (N = 50)
Injection site
Ecchymosisb 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1)
Painc 70 (55–82) 46 (32–61) 24 (13–38) 0.0 (0.0–7.1)
Rednessb 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1)
Swellingb 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1)
Systemic
Arthralgiacd 8.0 (2.2–19) 6.0 (1.3–17) 2.0 (0.1–11) 0.0 (0.0–7.1)
Fatiguecd 42 (28–57) 36 (23–51) 6.0 (1.3–17) 0.0 (0.0–7.1)
Gastrointestinalc 12 (4.5–24) 12 (4.5–24) 0.0 (0.0–7.1) 0.0 (0.0–7.1)
Headachec 28 (16–43) 22 (11–36) 6.0 (1.3–17) 0.0 (0.0–7.1)
Myalgiacd 22 (11–36) 18 (8.6–31) 4.0 (0.5–14) 0.0 (0.0–7.1)
Table 5 Solicited injection site and systemic symptoms in
response to vaccination (Continued)
Shiveringcd 4.0 (0.5–14) 2.0 (0.1–11) 0.0 (0.0–7.1) 2.0 (0.1–11)
Temperaturee 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1) 0.0 (0.0–7.1)
aValues reported at two significant figures.
bGrade 1, >20– ≤ 50 mm; Grade 2, >50– ≤ 100 mm; and Grade 3, >100 mm.
cGrade 1, “easily tolerated” (“painful on touch” for injection site pain); Grade 2,
“interferes with normal activity” (or “painful when limb is moved” for injection
site pain); and Grade 3, “prevents normal activity” (or “considerable pain at
rest” for injection site pain).
dSymptom was generalised/widespread.
eGrade 1, 38.0– < 38.5°C; Grade 2, 38.5– < 39.0°C; and Grade 3, 39.0– ≤ 40.0°C.
No subjects reported temperature above 40°C.
CI, confidence interval; TIV, trivalent influenza vaccine; TIV/AS03, AS03-
adjuvanted trivalent influenza vaccine.
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It could be that a CD8+ T-cell response occurred but
peaked before Day 21, as suggested by our preliminary data
showing CD8+ T-cell responses to A(H1N1)pdm09 vaccine
on Day 7 (unpublished data). Alternatively, an optimal
response ex vivo may require re-stimulation with a
major histocompatibility complex-presented antigen by
using infected cells instead of an inert split antigen. In
another study on TIV, a CD8+ T-cell response was de-
tected on Days 14 and 28 after vaccination using in-
fected cell re-stimulation [40].
No changes in the frequencies of influenza-specific
CD4+ T-cells expressing the cytolytic mediator Gran-
zyme B (and IFN-γ, and/or IL-2) were detected during
the study, suggesting that the vaccines had no effect on
influenza-specific cytotoxic T cells. However, in other ex-
periments, increased levels of Granzyme B activity have
been observed in PBMC lysates (re-stimulated ex vivo
with live influenza virus) in response to vaccination in
older adults and which may have correlated with protec-
tion [27,41]. The lack of a detectable effect on Granzyme
B in our study may be due to differences in method-
ology, in particular the nature of the ex vivo stimulus or
the exclusion in our assay of natural killer cells which
contributed to the Granzyme B activity measured else-
where [41]. In contrast, more than half the vaccine
strain-specific T cells expressed IFN-γ. The frequencies
of these IFN-γ+ CD4+ T cells appeared to increase post-
vaccination, and they may have had the potential to
exert some B-cell independent activity [42].
Although the study was not powered to compare
humoral immune responses between groups, the results
indicate an enhancing effect of AS03 on HI and neutra-
lising antibody responses to TIV strains. Significantly
enhanced antibody responses in older adults have been
observed with AS03-adjuvanted A(H5N1) [21] and A
(H1N1)pdm09 influenza vaccines [22]. The absence of
substantial correlations between the magnitude of the
antibody and CD4+ T-cell responses to vaccination was
not unexpected. This absence has been observed before
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A(H5N1) pandemic vaccines [43-46]. In contrast, correla-
tions have been identified after boosting with A(H5N1)
prime/boost influenza vaccination regimens [39,46], and by
examining particular CD4+ T-cell phenotypes [47]. In this
current study, memory T helper cells for the antibody re-
sponse may have only represented a minor part of vaccine-
strain specific T-cell response.
The incidence of some solicited symptoms was higher
for TIV/AS03 compared with TIV in ≥65 year old sub-
jects, but symptoms were mainly mild to moderate in
nature. Furthermore, the incidences of most symptoms
in the TIV/AS03(≥65) group were within the range for
the TIV(18 − 40) group. The tolerability of TIV/AS03 was
suggested by the similar incidences of unsolicited symp-
toms in the three groups and the lack of any clinically-
observable safety concerns. These findings are consistent
with a recent larger clinical study of AS03-adjuvanted sea-
sonal influenza vaccine [30], and with clinical studies on
AS03-adjuvanted A(H5N1) [21] and A(H1N1)pdm09 vac-
cines [22,48] which also indicated that AS03-adjuvanted
vaccines were well tolerated in older adults.
Other research into influenza immune responses
[3,26,27,49,50] indicate that, in addition to humoral re-
sponses, T-cell responses could contribute to vaccine-
mediated protection in older adults. Moreover, two recent
studies have identified relationships between influenza
disease severity and pre-existing disease strain-specific
T-cells, in adults without pre-existing disease strain-
specific antibodies [28,29]. In a prospective study of
adults (>18 years old) who became naturally-infected
with A(H1N1)pdm09, disease severity was inversely
correlated with pre-existing A(H1N1)pdm09-specific
CD8+, but not CD4+, T cells [29]; whereas in a study in
which adults (18–45 years old) were subjected to A(H3N2)
or A(H1N1)-virus challenge, disease severity was inversely
correlated with pre-existing challenge virus-specific CD4+,
but not CD8+, T cells [28]. Although those contrasting re-
sults may be related to the different methodologies used
(natural infection versus challenge; live virus versus pep-
tides for identifying specific T cells with restimulation cell
cultures) [29], the second study revealed a potential role of
CD4+ T cells in protection, perhaps because these cells had
direct cytotoxic activity or because they supported a CD8+
T-cell response through the expression of IFN-γ [28,51].
Therefore the magnitude of the influenza-specific CD4+ T-
cell response enhanced by AS03 in the seasonal vaccine
may be directly relevant to increasing protection against
disease in older adults.
Conclusions
TIV/AS03 is superior to TIV in terms of vaccine
antigen-specific CD4+ T-cell responses in ≥65 years-old
adults on Day 21 post-vaccination. This positive effect ofAS03 on the CD4+ T-cell response to influenza vaccine
strains in older adults could confer benefit in protection
against clinical influenza disease in this population.
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